176.93 USD
+1.19 (+0.68%)
177 USD
+0.07 (+0.04%)
JAZZ gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. There are concerns on the financial health of JAZZ while its profitability can be described as average. JAZZ has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
JAZZ had positive earnings in the past year.
In the past year JAZZ had a positive cash flow from operations.
In multiple years JAZZ reported negative net income over the last 5 years.
JAZZ had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
With a decent Return On Assets value of -3.24%, JAZZ is doing good in the industry, outperforming 73.96% of the companies in the same industry.
With a decent Return On Equity value of -9.31%, JAZZ is doing good in the industry, outperforming 74.48% of the companies in the same industry.
JAZZ has a better Return On Invested Capital (3.95%) than 82.29% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for JAZZ is significantly below the industry average of 12.71%.
The 3 year average ROIC (3.85%) for JAZZ is below the current ROIC(3.95%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.24% | ||
| ROE | -9.31% | ||
| ROIC | 3.95% |
ROA(3y)2.08%
ROA(5y)1.44%
ROE(3y)5.84%
ROE(5y)3.15%
ROIC(3y)3.85%
ROIC(5y)4.24%
1.3 Margins
In the last couple of years the Profit Margin of JAZZ has declined.
JAZZ has a better Operating Margin (10.92%) than 82.81% of its industry peers.
JAZZ's Operating Margin has declined in the last couple of years.
JAZZ's Gross Margin of 88.49% is amongst the best of the industry. JAZZ outperforms 90.63% of its industry peers.
In the last couple of years the Gross Margin of JAZZ has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.92% | ||
| PM (TTM) | N/A | ||
| GM | 88.49% |
OM growth 3Y11.44%
OM growth 5Y-6.23%
PM growth 3YN/A
PM growth 5Y-10.68%
GM growth 3Y1.26%
GM growth 5Y-1.09%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so JAZZ is destroying value.
Compared to 1 year ago, JAZZ has less shares outstanding
The number of shares outstanding for JAZZ has been increased compared to 5 years ago.
JAZZ has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of 1.58, we must say that JAZZ is in the distress zone and has some risk of bankruptcy.
JAZZ has a Altman-Z score (1.58) which is in line with its industry peers.
JAZZ has a debt to FCF ratio of 4.33. This is a neutral value as JAZZ would need 4.33 years to pay back of all of its debts.
JAZZ has a better Debt to FCF ratio (4.33) than 82.81% of its industry peers.
JAZZ has a Debt/Equity ratio of 1.09. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 1.09, JAZZ is doing worse than 72.40% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.09 | ||
| Debt/FCF | 4.33 | ||
| Altman-Z | 1.58 |
ROIC/WACC0.55
WACC7.23%
2.3 Liquidity
JAZZ has a Current Ratio of 1.65. This is a normal value and indicates that JAZZ is financially healthy and should not expect problems in meeting its short term obligations.
JAZZ's Current ratio of 1.65 is on the low side compared to the rest of the industry. JAZZ is outperformed by 67.71% of its industry peers.
A Quick Ratio of 1.44 indicates that JAZZ should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.44, JAZZ is not doing good in the industry: 63.54% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.65 | ||
| Quick Ratio | 1.44 |
3. Growth
3.1 Past
The earnings per share for JAZZ have decreased strongly by -58.39% in the last year.
The Earnings Per Share has been growing slightly by 5.47% on average over the past years.
The Revenue has been growing slightly by 4.14% in the past year.
Measured over the past years, JAZZ shows a quite strong growth in Revenue. The Revenue has been growing by 13.48% on average per year.
EPS 1Y (TTM)-58.39%
EPS 3Y9.3%
EPS 5Y5.47%
EPS Q2Q%23%
Revenue 1Y (TTM)4.14%
Revenue growth 3Y9.56%
Revenue growth 5Y13.48%
Sales Q2Q%6.74%
3.2 Future
The Earnings Per Share is expected to grow by 7.82% on average over the next years.
Based on estimates for the next years, JAZZ will show a small growth in Revenue. The Revenue will grow by 7.13% on average per year.
EPS Next Y-74.64%
EPS Next 2Y3.08%
EPS Next 3Y5.52%
EPS Next 5Y7.82%
Revenue Next Year4.41%
Revenue Next 2Y5.24%
Revenue Next 3Y5.81%
Revenue Next 5Y7.13%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 21.68, JAZZ is valued on the expensive side.
79.17% of the companies in the same industry are more expensive than JAZZ, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 25.47, JAZZ is valued at the same level.
A Price/Forward Earnings ratio of 7.86 indicates a rather cheap valuation of JAZZ.
Based on the Price/Forward Earnings ratio, JAZZ is valued cheaper than 90.63% of the companies in the same industry.
JAZZ's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 34.42.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.68 | ||
| Fwd PE | 7.86 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of JAZZ indicates a rather cheap valuation: JAZZ is cheaper than 83.85% of the companies listed in the same industry.
90.63% of the companies in the same industry are more expensive than JAZZ, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 8.68 | ||
| EV/EBITDA | 11.71 |
4.3 Compensation for Growth
The decent profitability rating of JAZZ may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)3.97
EPS Next 2Y3.08%
EPS Next 3Y5.52%
5. Dividend
5.1 Amount
No dividends for JAZZ!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
176.93
+1.19 (+0.68%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners106.51%
Inst Owner Change-3.3%
Ins Owners2.49%
Ins Owner Change-0.76%
Market Cap10.75B
Revenue(TTM)4.16B
Net Income(TTM)-368.48M
Analysts84.8
Price Target193.81 (9.54%)
Short Float %8.7%
Short Ratio6.03
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)14.15%
Min EPS beat(2)-6.35%
Max EPS beat(2)34.65%
EPS beat(4)2
Avg EPS beat(4)-6.25%
Min EPS beat(4)-64.64%
Max EPS beat(4)34.65%
EPS beat(8)4
Avg EPS beat(8)-5.06%
EPS beat(12)4
Avg EPS beat(12)-14.55%
EPS beat(16)7
Avg EPS beat(16)-9.8%
Revenue beat(2)0
Avg Revenue beat(2)-1.26%
Min Revenue beat(2)-2.09%
Max Revenue beat(2)-0.43%
Revenue beat(4)1
Avg Revenue beat(4)-3.13%
Min Revenue beat(4)-10.66%
Max Revenue beat(4)0.66%
Revenue beat(8)1
Avg Revenue beat(8)-2.61%
Revenue beat(12)1
Avg Revenue beat(12)-2.27%
Revenue beat(16)3
Avg Revenue beat(16)-2.04%
PT rev (1m)1.64%
PT rev (3m)2.12%
EPS NQ rev (1m)11.04%
EPS NQ rev (3m)12.1%
EPS NY rev (1m)-0.91%
EPS NY rev (3m)10.64%
Revenue NQ rev (1m)-0.93%
Revenue NQ rev (3m)-0.68%
Revenue NY rev (1m)0.05%
Revenue NY rev (3m)-0.28%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.68 | ||
| Fwd PE | 7.86 | ||
| P/S | 2.59 | ||
| P/FCF | 8.68 | ||
| P/OCF | 7.73 | ||
| P/B | 2.72 | ||
| P/tB | N/A | ||
| EV/EBITDA | 11.71 |
EPS(TTM)8.16
EY4.61%
EPS(NY)22.52
Fwd EY12.73%
FCF(TTM)20.39
FCFY11.52%
OCF(TTM)22.9
OCFY12.94%
SpS68.42
BVpS65.15
TBVpS-40.06
PEG (NY)N/A
PEG (5Y)3.97
Graham Number109.37
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.24% | ||
| ROE | -9.31% | ||
| ROCE | 5% | ||
| ROIC | 3.95% | ||
| ROICexc | 5.1% | ||
| ROICexgc | 55.75% | ||
| OM | 10.92% | ||
| PM (TTM) | N/A | ||
| GM | 88.49% | ||
| FCFM | 29.8% |
ROA(3y)2.08%
ROA(5y)1.44%
ROE(3y)5.84%
ROE(5y)3.15%
ROIC(3y)3.85%
ROIC(5y)4.24%
ROICexc(3y)4.89%
ROICexc(5y)5.68%
ROICexgc(3y)31.42%
ROICexgc(5y)35.77%
ROCE(3y)4.87%
ROCE(5y)5.36%
ROICexgc growth 3Y32.25%
ROICexgc growth 5Y-7.79%
ROICexc growth 3Y35.45%
ROICexc growth 5Y-6.86%
OM growth 3Y11.44%
OM growth 5Y-6.23%
PM growth 3YN/A
PM growth 5Y-10.68%
GM growth 3Y1.26%
GM growth 5Y-1.09%
F-Score5
Asset Turnover0.37
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.09 | ||
| Debt/FCF | 4.33 | ||
| Debt/EBITDA | 3.8 | ||
| Cap/Depr | 22.29% | ||
| Cap/Sales | 3.68% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 122.16% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.65 | ||
| Quick Ratio | 1.44 | ||
| Altman-Z | 1.58 |
F-Score5
WACC7.23%
ROIC/WACC0.55
Cap/Depr(3y)31.05%
Cap/Depr(5y)47.54%
Cap/Sales(3y)5.31%
Cap/Sales(5y)6.69%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-58.39%
EPS 3Y9.3%
EPS 5Y5.47%
EPS Q2Q%23%
EPS Next Y-74.64%
EPS Next 2Y3.08%
EPS Next 3Y5.52%
EPS Next 5Y7.82%
Revenue 1Y (TTM)4.14%
Revenue growth 3Y9.56%
Revenue growth 5Y13.48%
Sales Q2Q%6.74%
Revenue Next Year4.41%
Revenue Next 2Y5.24%
Revenue Next 3Y5.81%
Revenue Next 5Y7.13%
EBIT growth 1Y-35.5%
EBIT growth 3Y22.09%
EBIT growth 5Y6.42%
EBIT Next Year-54.85%
EBIT Next 3Y4.81%
EBIT Next 5Y9.15%
FCF growth 1Y42.84%
FCF growth 3Y22.51%
FCF growth 5Y17.8%
OCF growth 1Y9.88%
OCF growth 3Y21.49%
OCF growth 5Y12.45%
JAZZ PHARMACEUTICALS PLC / JAZZ FAQ
Can you provide the ChartMill fundamental rating for JAZZ PHARMACEUTICALS PLC?
ChartMill assigns a fundamental rating of 4 / 10 to JAZZ.
What is the valuation status of JAZZ PHARMACEUTICALS PLC (JAZZ) stock?
ChartMill assigns a valuation rating of 6 / 10 to JAZZ PHARMACEUTICALS PLC (JAZZ). This can be considered as Fairly Valued.
Can you provide the profitability details for JAZZ PHARMACEUTICALS PLC?
JAZZ PHARMACEUTICALS PLC (JAZZ) has a profitability rating of 6 / 10.
How financially healthy is JAZZ PHARMACEUTICALS PLC?
The financial health rating of JAZZ PHARMACEUTICALS PLC (JAZZ) is 3 / 10.
Can you provide the expected EPS growth for JAZZ stock?
The Earnings per Share (EPS) of JAZZ PHARMACEUTICALS PLC (JAZZ) is expected to decline by -74.64% in the next year.